Estrogens, esterified
Identification
- Name
- Estrogens, esterified
- Accession Number
- DB09381
- Type
- Small Molecule
- Groups
- Approved
- Description
Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis.
- Synonyms
- Esterified Estrogens
- Estrogens, Esterified Component of Menrium
- Estrogens,esterified
- Menrium Component Estrogens, Esterified
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Estragyn Tablet 0.625 mg Oral Searchlight Pharma Inc 1974-12-31 Not applicable Canada 
Estragyn Tablet 0.3 mg Oral Searchlight Pharma Inc 1980-12-31 Not applicable Canada Neo Estrone Tab 1.25mg Tablet 1.25 mg Oral Neolab Inc 1974-12-31 2008-04-02 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Menest Tablet, film coated 0.625 mg/1 Oral Pfizer Laboratories Div Pfizer Inc 1977-09-28 Not applicable US 
Menest Tablet 0.625 mg/1 Oral Physicians Total Care, Inc. 2008-09-05 Not applicable US Menest Tablet, film coated 0.3 mg/1 Oral Pfizer Laboratories Div Pfizer Inc 1977-09-28 Not applicable US Menest Tablet 0.3 mg/1 Oral Physicians Total Care, Inc. 2010-12-09 Not applicable US Menest Tablet, film coated 2.5 mg/1 Oral Pfizer Laboratories Div Pfizer Inc 2018-09-17 Not applicable US Menest Tablet, film coated 0.625 mg/1 Oral Avera McKennan Hospital 2015-11-23 2018-06-26 US Menest Tablet 1.25 mg/1 Oral Physicians Total Care, Inc. 2010-12-16 Not applicable US Menest Tablet, film coated 1.25 mg/1 Oral Pfizer Laboratories Div Pfizer Inc 1977-09-28 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Covaryx Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet, coated Oral Centrix Pharmaceutical 2007-04-01 Not applicable US 
Covaryx Hs Estrogens, esterified (0.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet, coated Oral Centrix Pharmaceutical 2007-04-01 Not applicable US Eemt Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet, coated Oral Creekwood Pharmaceuticals, Inc. 2011-09-01 Not applicable US Eemt H.S. Estrogens, esterified (0.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet, coated Oral Physicians Total Care, Inc. 2006-06-27 2013-01-15 US Eemt Hs Estrogens, esterified (0.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet, coated Oral Creekwood Pharmaceuticals, Inc. 2011-09-01 Not applicable US Essian Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet Oral Prasco, Laboratories 2005-09-01 2010-01-31 US Essian H.S. Estrogens, esterified (0.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet Oral Prasco, Laboratories 2005-09-01 2010-01-31 US Esterified Estrogens and Methyltestosterone Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet Oral ANIP Acquisition Company 2010-12-22 2010-12-10 US Esterified Estrogens and Methyltestosterone Estrogens, esterified (0.625 mg/1) + Methyltestosterone (1.25 mg/1) Tablet Oral ANI Pharmaceuticals, Inc. 2010-12-22 Not applicable US 
Esterified Estrogens and Methyltestosterone Estrogens, esterified (1.25 mg/1) + Methyltestosterone (2.5 mg/1) Tablet Oral Method Pharmaceuticals 2017-08-15 Not applicable US - International/Other Brands
- Amnestrogen / Estratab / Evex / Femogen
- Categories
- UNII
- 3ASP8Q3768
- CAS number
- Not Available
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Esterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the body. It is also indicated for the treatment of symptoms of breast cancer in both men and women. In men it can be used for the treatment of advanced prostate cancer. It is also indicated for the treatment of menopausal symptoms.
- Associated Conditions
- Pharmacodynamics
Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause.
- Mechanism of action
Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones.
- Absorption
Readily absorbed after oral administration. High concentrations of estrone are achieved with oral administration, whereas higher concentrations of estradiol are generally achieved after percutaneous absorption. Although vaginal products (such as gel, rings, etc.) are administered locally, they achieve high serum concentrations.
- Volume of distribution
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentration in the sex hormone target organs.
- Protein binding
Approximately 95-98% of estradiol is bound loosely to albumin or tightly to sex hormone binding globulin.
- Metabolism
Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women.
- Route of elimination
Mainly urinary as estradiol, estrone, estriol, and their glucuronide and sulfate conjugates.
- Half life
Half-life varies, it is in the range 1-2 hr.
- Clearance
There is variation in the clearance rate depends on each estrogen individual: estradiol-17β: 580 L/day/m2 estrone: 4050 L/day/m2 estriol: 1110 L/day/m2
- Toxicity
LD50 IP 325 mg/Kg (rat). LD50 IV 1740 mg/Kg (mouse). LD50 oral >5000 mg/Kg (rat).
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin Estrogens, esterified may decrease the anticoagulant activities of (R)-warfarin. (S)-Warfarin Estrogens, esterified may decrease the anticoagulant activities of (S)-Warfarin. 3,5-diiodothyropropionic acid The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Estrogens, esterified. 4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be decreased when combined with Estrogens, esterified. 5-androstenedione The metabolism of Estrogens, esterified can be decreased when combined with 5-androstenedione. 6-Deoxyerythronolide B The metabolism of Estrogens, esterified can be decreased when combined with 6-Deoxyerythronolide B. 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Estrogens, esterified. 7-ethyl-10-hydroxycamptothecin The metabolism of Estrogens, esterified can be decreased when combined with 7-ethyl-10-hydroxycamptothecin. 9-aminocamptothecin The metabolism of 9-aminocamptothecin can be decreased when combined with Estrogens, esterified. Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Estrogens, esterified. - Food Interactions
- Not Available
References
- General References
- External Links
- PubChem Substance
- 347910451
- Wikipedia
- Esterified_estrogens
- AHFS Codes
- 68:16.04 — Estrogens
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Hot Flushes, Menopause, Postmenopause 1 2 Completed Treatment Menopause 1 2 Terminated Treatment Cancer, Breast 1 2 Terminated Treatment Menopause 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Tablet, coated Oral Tablet Oral Tablet Oral 0.3 mg Tablet Oral 0.625 mg Tablet Oral 0.3 mg/1 Tablet Oral 0.625 mg/1 Tablet Oral 1.25 mg/1 Tablet, film coated Oral 0.3 mg/1 Tablet, film coated Oral 0.625 mg/1 Tablet, film coated Oral 1.25 mg/1 Tablet, film coated Oral 2.5 mg/1 Tablet Oral 1.25 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
Drug created on November 30, 2015 12:10 / Updated on February 17, 2019 16:46